Nutrition Support Consultant features issues pertinent to the clinical aspects of pharmacy nutrition support practice.
Get full access to this article
View all access options for this article.
References
1.
EstoupM.Approaches and limitations of medication delivery in patients with enteral feeding tubes.Crit Care Nurse.1994; 14: 68–72,77–9.
2.
GoraM.L., TschampelM.M., ViscontiJ.A.Considerations of drug therapy in patients receiving enteral nutrition.Nutr Clin Pract.1989; 4: 105–10.
3.
SmithC.H., BidlackW.R.Dietary concerns associated with the use of medications.J Am Diet Assoc.1984; 84: 901–14.
4.
EngleK.K., HannawaT.E.Techniques for administering oral medications to critical care patients receiving continuous enteral nutrition.Am J Health Syst Pharm.1999; 56: 1441–4.
5.
BeckwithM.C., BartonR.G., GravesC.A guide to drug therapy in patients with enteral feeding tubes: Dosage form selection and administration methods.Hosp Pharm.1997; 32: 57–64.
HillD.B., HendersonL.M., McClainC.J.Osmotic diarrhea induced by sugarfree theophylline solution in critically ill patients.JPEN J Parenter Enteral Nutr.1991; 15: 332–6.
9.
EdesT.E., WalkB.E., AustinJ.L.Diarrhea in tube-fed patients: Feeding formula not necessarily the cause.Am J Med.1990; 88: 91–3.
10.
DickersonR.N., MelnikG.Osmolality of oral drug solutions and suspensions.Am J Hosp Pharm.1988; 45: 832–4.
11.
HoltzL., MiltonJ., SturekJ.K.Compatibility of medications with enteral feedings.JPEN J Parenter Enteral Nutr.1987; 11: 183–6.
12.
NiemiecP.W.Jr., VanderveenTW, MorrisonJI, Gastrointestinal disorders caused by medication and electrolyte solution osmolality during enteral nutrition.JPEN J Parenter Enteral Nutr.1983; 7: 387–9.
13.
WhiteK.C., HarkavyK.L.Hypertonic formula resulting from added oral medications.Am J Dis Child.1982; 136: 931–3.
14.
KeohaneP.P., AttrillH., LoveM.Relation between osmolality of diet and gastrointestinal side effects in enteral nutrition.BMJ (Clin Res Ed).1984; 288: 678–80.
15.
PesolaG.R., HoggJ.E., EissaN.Hypertonic nasogastric tube feedings: Do they cause diarrhea?Crit Care Med.1990; 18: 1378–82.
DickersonR.N., TidwellA.C., BrownR.O.Adverse effects from inappropriate medication administration via a jejunostomy feeding tube.Nutr Clin Pract.2003; 18: 402–8.
18.
MitchellJ.E.Oral dosage forms that should not be crushed: 1998 update.Hosp Pharm.1998; 33: 399–415.
19.
ChunA.H., ShiH.H., AchariR.Lansoprazole: Administration of the contents of a capsule dosage formulation through a nasogastric tube.Clin Ther.1996; 18: 833–42.
20.
PhillipsJ.O., OlsenK.M., RebuckJ.A.A randomized, pharmacokinetic and pharmacodynamic, cross-over study of duodenal or jejunal administration compared to nasogastric administration of omeprazole suspension in patients at risk for stress ulcers.Am J Gastroenterol.2001; 96: 367–72.
21.
McAndrewsK.L.Jr., Eastham JH. Omeprazole and lansoprazole suspensions for nasogastric administration.Am J Health Syst Pharm.1999; 56: 81.
22.
DunnA., WhiteC.M., ReddyP.Delivery of omeprazole and lansoprazole granules through a nasogastric tube in vitro.Am J Health Syst Pharm.1999; 56: 2327–30.
23.
QuerciaR.A., FanC., LiuX.Stability of omeprazole in an extemporaneously prepared oral liquid.Am J Health Syst Pharm.1997; 54: 1833–6.
24.
CutieA.J., AltmanE., LenkelL.Compatibility of enteral products with commonly employed drug additives.JPEN J Parenter Enteral Nutr.1983; 7: 186–91.
25.
BurnsP.E., McCallL., WirschingR.Physical compatibility of enteral formulas with various common medications.J Am Diet Assoc.1988; 88: 1094–6.
26.
AltmanE., CutieA.J.Compatibility of enteral products with commonly employed drug additives.Nutr Supp Serv.1984; 4: 8–17.
27.
FagermanK.E., BallouA.E.Drug compatibilities with enteral feeding solutions coadministered by tube.Nutr Supp Serv.1988; 8: 31–2.
28.
HealyD.P., BrodbeckM.C., ClendeningC.E.Ciprofloxacin absorption is impaired in patients given enteral feedings orally and via gastrostomy and jejunostomy tubes.Antimicrob Agents Chemother.1996; 40: 6–10.
29.
MuellerB.A., BriertonD.G., AbelS.R.Effect of enteral feeding with ensure on oral bioavailabilities of ofloxacin and ciprofloxacin.Antimicrob Agents Chemother.1994; 38: 2101–5.
30.
MimozO., BinterV., JacolotA.Pharmacokinetics and absolute bioavailability of ciprofloxacin administered through a nasogastric tube with continuous enteral feeding to critically ill patients.Intensive Care Med.1998; 24: 1047–51.
31.
FarajiB., YuP.P.Serum phenytoin levels of patients on gastrostomy tube feeding.J Neurosci Nurs.1998; 30: 55–9.
32.
BauerL.A.Interference of oral phenytoin absorption by continuous nasogastric feedings.Neurology.1982; 32: 570–2.
SneedR.C., MorganW.T.Interference of oral phenytoin absorption by enteral tube feedings.Arch Phys Med Rehabil.1988; 69: 682–4.
35.
HooksM.A., LongeR.L., TaylorA.T.Recovery of phenytoin from an enteral nutrient formula.Am J Hosp Pharm.1986; 43: 685–8.
36.
CacekA.T., DeVitoJ.M., KoonceJ.R.In vitro evaluation of nasogastric administration methods for phenytoin.Am J Hosp Pharm.1986; 43: 689–92.
37.
PenrodL.E., AllenJ.B., CabacunganL.R.Warfarin resistance and enteral feedings: Two case reports and a supporting in vitro study.Arch Phys Med Rehabil.2001; 82: 1270–3.
38.
PetretichD.A.Reversal of Osmolitewarfarin interaction by changing warfarin administration time.Clin Pharm.1990; 9: 93.
39.
KuhnT.A., GarnettW.R., WellsB.K.Recovery of warfarin from an enteral nutrient formula.Am J Hosp Pharm.1989; 46: 1395–9.
40.
CohnS.M., SawyerM.D., BurnsG.A.Enteric absorption of ciprofloxacin during tube feeding in the critically ill.J Antimicrob Chemother.1996; 38: 871–6.
41.
NyffelerM.S.Ciprofloxacin use in the enterally fed patient.Nutr Clin Pract.1999; 14: 73–7.
42.
PughC.B.Phenytoin and enteral feedings: A clinically significant interaction.Hosp Pharm.1989; 24: 562–9.
43.
BertinoJ.S., NadererO.Is the phenytoin-enteral feeding formula interaction a myth? [letter].Nutr Clin Pract.1996; 11: 175–6.
44.
MarvelM.E., BertinoJ.S.Jr.Comparative effects of an elemental and a complex enteral feeding formulation on the absorption of phenytoin suspension.JPEN J Parenter Enteral Nutr.1991; 15: 316–8.
45.
KruegerK.A., GarnettW.R., ComstockT.J.Effect of two administration schedules of an enteral nutrient formula on phenytoin bioavailability.Epilepsia.1987; 28: 706–12.
46.
HattonJ., MagnussonB.Response to Drs. Bertino and Naderer [letter].Nutr Clin Pract.1996; 11: 176.
